Kiniksa Pharmaceuticals Ltd (KNSA) Reports Strong Revenue Growth in Q4 and Full-Year 2023 [Yahoo! Finance]
Kiniksa Pharmaceuticals, Ltd. - Class A (KNSA)
Last kiniksa pharmaceuticals, ltd. - class a earnings: 8/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
2024 Revenue Forecast : Projected ARCALYST net product revenue of $360 - $380 million, indicating approximately 59% growth at the midpoint. Research and Development : Phase 2 rheumatoid arthritis data from Cohort 4 and a new development indication for abiprubart expected in April 2024. Financial Position : Cash reserves of $206.4 million expected to fund operations into at least 2027. Net Income : Reported net income of $25.2 million for Q4 and $14.1 million for the full year. Warning! GuruFocus has detected 5 Warning Signs with KNSA. On February 28, 2024, Kiniksa Pharmaceuticals Ltd ( NASDAQ:KNSA ) released its 8-K filing , detailing the fourth quarter and full-year financial results for 2023. The clinical-stage biopharmaceutical company, known for its focus on developing therapeutic medicines for patients with debilitating diseases, reported significant growth in net product revenue, particularly from its lead product ARCALYST (rilonacept), which is approved for the treat
Show less
Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals, Ltd. - Class A news events
Weekly update
A roundup of the hottest topics
KNSA
News
- Analyst Estimates: Here's What Brokers Think Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) After Its First-Quarter Report [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its price target raised by analysts at Evercore ISI from $25.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.MarketBeat
- Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution [Yahoo! Finance]Yahoo! Finance
KNSA
Earnings
- 4/23/24 - Miss
KNSA
Sec Filings
- 4/25/24 - Form 10-Q
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEFA14A
- KNSA's page on the SEC website